论文部分内容阅读
目的:探索辛伐他汀联合低分子肝素对慢性心力衰竭(CHF)患者的D-二聚体、N-末端脑钠肽前体(NT-proBNP)、左室射血分数(LVEF)、左室舒末内径、血清反应蛋白(CRP)、血浆纤维蛋白原(FB)、血清总胆固醇(TC)及低密度脂蛋白胆固醇(LDL-C)的影响。方法:选择我院自2010年4月至2014年7月间收治的患有CHF患者80例,按照随机数表法分成治疗组和对照组,各40例。两组均给予常规治疗,治疗组在常规治疗的基础上加用辛伐他汀和低分子肝素,治疗两个月。对比两组患者治疗前后D-二聚体、NT-proBNP、LVEF、左室舒末内径、CRP、FB、TC和LDL-C水平。结果:与治疗前相比,对照组患者治疗后的D-二聚体、NT-proBNP、LVEF、左室舒末内径、CRP、FB、TC和LDL-C水平均无明显改善,而治疗组患者上述各项指标均显著改善,差异均具有统计学意义(均P<0.05)。结论:临床上应用辛伐他汀联合低分子肝素可以有效改善CHF患者的相关指标,对于疾病的治疗具有重要作用,值得在临床上应用及推广。
Objective: To investigate the effects of simvastatin combined with low molecular weight heparin on the levels of D-dimer, NT-proBNP, LVEF, left ventricular End-diastolic diameter, serum CRP, FB, TC and LDL-C were measured. Methods: Eighty patients with CHF admitted to our hospital from April 2010 to July 2014 were divided into treatment group and control group according to the random number table method, 40 cases each. Both groups were given conventional treatment, the treatment group on the basis of conventional treatment with simvastatin and low molecular weight heparin for two months. D-dimer, NT-proBNP, LVEF, left ventricular end-diastolic diameter, CRP, FB, TC and LDL-C levels before and after treatment were compared between the two groups. Results: There was no significant improvement in the levels of D-dimer, NT-proBNP, LVEF, left ventricular end-diastolic dimension, CRP, FB, TC and LDL-C in the control group after treatment The above indicators of patients were significantly improved, the differences were statistically significant (P <0.05). Conclusion: The clinical application of simvastatin combined with low molecular weight heparin can effectively improve the relevant indexes of patients with CHF, which play an important role in the treatment of the disease and are worthy of clinical application and promotion.